Compare TARS & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARS | PBH |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2020 | 2004 |
| Metric | TARS | PBH |
|---|---|---|
| Price | $59.11 | $49.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $89.00 | $75.33 |
| AVG Volume (30 Days) | ★ 1.2M | 642.2K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ 3.91 |
| Revenue | $451,360,000.00 | ★ $975,777,000.00 |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | $4.31 |
| P/E Ratio | ★ N/A | $12.95 |
| Revenue Growth | ★ 146.71 | 36.77 |
| 52 Week Low | $38.51 | $42.62 |
| 52 Week High | $85.25 | $77.45 |
| Indicator | TARS | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 54.06 |
| Support Level | $59.16 | $44.86 |
| Resistance Level | $67.14 | $49.79 |
| Average True Range (ATR) | 4.27 | 1.52 |
| MACD | -0.78 | 0.24 |
| Stochastic Oscillator | 31.00 | 59.78 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.